Cargando…

BioBanking - The Holy Grail of novel drug and diagnostic developments?

The ever increasing social cost that society pays for illness and disease are currently steadily increasing in many countries in the world today. These changes in society becomes a major financial burden that activates politicians and health care organizations in order to find new solutions. Biobank...

Descripción completa

Detalles Bibliográficos
Autor principal: Marko-Varga, György
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164607/
https://www.ncbi.nlm.nih.gov/pubmed/21884630
http://dx.doi.org/10.1186/2043-9113-1-14
_version_ 1782211051493785600
author Marko-Varga, György
author_facet Marko-Varga, György
author_sort Marko-Varga, György
collection PubMed
description The ever increasing social cost that society pays for illness and disease are currently steadily increasing in many countries in the world today. These changes in society becomes a major financial burden that activates politicians and health care organizations in order to find new solutions. Biobanks are becoming the new powerful modality within the field of modern Life Science, that is expected to be important in the proactive awareness of patient health status. Biobanks are also expected to promote the developments of targeted treatments with personalized indicator assays, for effective use of Personalized Medicine treatments in the near future.
format Online
Article
Text
id pubmed-3164607
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31646072011-09-02 BioBanking - The Holy Grail of novel drug and diagnostic developments? Marko-Varga, György J Clin Bioinforma Editorial The ever increasing social cost that society pays for illness and disease are currently steadily increasing in many countries in the world today. These changes in society becomes a major financial burden that activates politicians and health care organizations in order to find new solutions. Biobanks are becoming the new powerful modality within the field of modern Life Science, that is expected to be important in the proactive awareness of patient health status. Biobanks are also expected to promote the developments of targeted treatments with personalized indicator assays, for effective use of Personalized Medicine treatments in the near future. BioMed Central 2011-05-13 /pmc/articles/PMC3164607/ /pubmed/21884630 http://dx.doi.org/10.1186/2043-9113-1-14 Text en Copyright ©2011 Marko-Varga; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Marko-Varga, György
BioBanking - The Holy Grail of novel drug and diagnostic developments?
title BioBanking - The Holy Grail of novel drug and diagnostic developments?
title_full BioBanking - The Holy Grail of novel drug and diagnostic developments?
title_fullStr BioBanking - The Holy Grail of novel drug and diagnostic developments?
title_full_unstemmed BioBanking - The Holy Grail of novel drug and diagnostic developments?
title_short BioBanking - The Holy Grail of novel drug and diagnostic developments?
title_sort biobanking - the holy grail of novel drug and diagnostic developments?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164607/
https://www.ncbi.nlm.nih.gov/pubmed/21884630
http://dx.doi.org/10.1186/2043-9113-1-14
work_keys_str_mv AT markovargagyorgy biobankingtheholygrailofnoveldruganddiagnosticdevelopments